EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Evaluation of [ 18 F]BIBD-300 as a Positron Emission Tomography Tracer for Poly(ADP-Ribose) Polymerase-1

Wei Zheng, Yong Huang iD, Yi Xie, Tingyu Yang, Xuebo Cheng, Hualong Chen, Chengze Li, Zeng Jiang, Ziyue Yu, Zhongjing Li, Lu Zhang, Leilei Yuan und 3 weitere

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Wei Zheng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Di…. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Poly (ADP-Ribose) Polymerase-1, Fluorine Radioisotopes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Capital Medical University, Beijing Municipal Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Compounds 8a-j were designed to adjust the mode of interaction and lipophilicity of FTT by scaffold hopping and changing the length of the alkoxy groups. Compounds 8a, 8d, 8g, and BIBD-300 were screened for high-affinity PARP-1 through enzyme inhibition assays and are worthy of further evaluation. PET imaging of MCF-7 subcutaneous tumors with moderate expression of PARP-1 showed that compared to [18F]FTT, [18F]8a, [18F]8d, and [18F]8g exhibited greater nonspecific uptake, a lower target-to-nontarget ratio, and severe defluorination, while [18F]BIBD-300 exhibited lower nonspecific uptake and a greater target-to-nontarget ratio. PET imaging of 22Rv1 subcutaneous tumors, which highly express PARP-1, confirmed that the uptake of [18F]BIBD-300 in normal organs, such as the liver, muscle, and bone, was lower than that of [18F]FTT, and the ratio of tumor-to-muscle and tumor-to-liver [18F]BIBD-300 was greater than that of [18F]FTT. The biodistribution results in mice with MCF-7 and 22Rv1 subcutaneous tumors further validated the results of PET imaging. Unlike [18F]FTT, which mainly relies on hepatobiliary clearance, [18F]BIBD-300, which has lower lipophilicity, undergoes a partial shift from hepatobiliary to renal clearance, providing the possibility for [18F]BIBD-300 to indicate liver cancer. The difference in the PET imaging results for [18F]FTT, [18F]BIBD-300, and [18F]8j in 22Rv1 mice and the corresponding molecular docking results further confirmed that subtle structural modifications in lipophilicity greatly optimize the properties of the tracer. Cell uptake experiments also demonstrated that [18F]BIBD-300 has a high affinity for PARP-1. Metabolized and unmetabolized [18F]FTT and [18F]BIBD-300 were detected in the brain, indicating that they could not accurately quantify the amount of PARP-1 in the brain. However, PET imaging of glioma showed that both [18F]FTT and [18F]BIBD-300 could accurately localize both in situ to C6 and U87MG tumors. Based on its potential advantages in the diagnosis of breast cancer, prostate cancer, and glioma, as well as liver cancer, [18F]BIBD-300 is a new option for an excellent PARP-1 tracer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyPoly (ADP-Ribose) Polymerase-1Fluorine RadioisotopesAnimalsHumansMiceFemaleTissue DistributionRadiopharmaceuticalsCell Line, TumorMice, NudePoly(ADP-ribose) Polymerase InhibitorsDrug DesignMice, Inbred BALB CMCF-7 Cells

Stichwörter der Autor:innen

[18F]BIBD-300[18F]FTTpoly(ADP-ribose) polymerasepositron emission tomographytracer

Substanzen

Poly (ADP-Ribose) Polymerase-1Fluorine RadioisotopesRadiopharmaceuticalsPARP1 protein, humanPoly(ADP-ribose) Polymerase InhibitorsFluorine-18

Autor:innen und Institutionen

  • Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing 100069, China.
  • Department of Nuclear Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518…
  • School of Pharmaceutical Science, Capital Medical University, Beijing 100069, China.
  • Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.

ORCID-Profile: Yong Huang, Zehui Wu

Förderung

  • Capital Medical University
  • Beijing Municipal Natural Science Foundation
  • National Natural Science Foundation of China
  • Shenzhen Clinical Research Center for Cancer
  • Shenzhen Science and Technology Program

Zitieren

APA

Zheng, W., Huang, Y., Xie, Y., Yang, T., Cheng, X., Chen, H., Li, C., Jiang, Z., Yu, Z., Li, Z., Zhang, L., Yuan, L., Liu, Y., Liang, Y., & Wu, Z. (2024). Design, Synthesis, and Evaluation of [ 18 F]BIBD-300 as a Positron Emission Tomography Tracer for Poly(ADP-Ribose) Polymerase-1. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00262

Vancouver

Zheng W, Huang Y, Xie Y, Yang T, Cheng X, Chen H, et al. Design, Synthesis, and Evaluation of [ 18 F]BIBD-300 as a Positron Emission Tomography Tracer for Poly(ADP-Ribose) Polymerase-1. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00262

BibTeX
@article{Zheng2024,
  author = {Zheng, Wei and Huang, Yong and Xie, Yi and Yang, Tingyu and Cheng, Xuebo and Chen, Hualong and Li, Chengze and Jiang, Zeng and Yu, Ziyue and Li, Zhongjing and Zhang, Lu and Yuan, Leilei and Liu, Yajing and Liang, Ying and Wu, Zehui},
  title = {Design, Synthesis, and Evaluation of [ 18 F]BIBD-300 as a Positron Emission Tomography Tracer for Poly(ADP-Ribose) Polymerase-1},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00262}
}
Kostenlos starten →